Cipla insulin lispro
Insulin lispro biosimilar developed by Not stated in the CDSCO list. Reference product Humalog.
About Cipla insulin lispro
Cipla holds Indian import permissions for insulin lispro from 2021, for the standard product and the two premixed forms, and from 2023 for an ultra-rapid version. The published Indian list does not name the manufacturer. Cipla's insulin range for India is built on imported products.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Cipla insulin lispro holds an approval, these are the other insulin lispro biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 1 | Not stated in the CDSCO list (Lupin insulin lispro) |
Chronology
- CDSCOSep 2021CDSCO permission granted
Sources
S012CDSCO, new drugs (r-DNA origin) approved for import and marketing, Jan 2020 to June 2026 (CT-18) Primary (regulator)
Planning insulin lispro biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant